Business Description
Alphamab Oncology
ISIN : KYG0330A1013
Share Class Description:
HKSE:09966: Ordinary SharesTotal Employee Number:
498Compare
Compare
Traded in other countries / regions
09966.Hong KongALMOF.USA3NK.Germany Index Membership
Hong Kong Stock Connect IPO Date
2019-12-12Description
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.33 | |||||
Equity-to-Asset | 0.77 | |||||
Debt-to-Equity | 0.16 | |||||
Debt-to-EBITDA | -2.03 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 10.81 | |||||
Beneish M-Score | -0.95 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 48.4 | |||||
3-Year EBITDA Growth Rate | 46.1 | |||||
3-Year EPS without NRI Growth Rate | 29.9 | |||||
3-Year FCF Growth Rate | 30 | |||||
3-Year Book Growth Rate | 1.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 14.92 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 46.23 | |||||
9-Day RSI | 51.19 | |||||
14-Day RSI | 53.01 | |||||
3-1 Month Momentum % | -9.89 | |||||
6-1 Month Momentum % | -14.24 | |||||
12-1 Month Momentum % | -23.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.02 | |||||
Quick Ratio | 3.68 | |||||
Cash Ratio | 3.4 | |||||
Days Inventory | 688.43 | |||||
Days Sales Outstanding | 33.5 | |||||
Days Payable | 345.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1 | |||||
Shareholder Yield % | 1.06 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 88.72 | |||||
Operating Margin % | -35.73 | |||||
Net Margin % | -33.51 | |||||
EBITDA Margin % | -26.05 | |||||
FCF Margin % | -28.87 | |||||
OCF Margin % | -22.96 | |||||
ROE % | -10.07 | |||||
ROA % | -7.97 | |||||
ROIC % | -23.91 | |||||
3-Year ROIIC % | -100.29 | |||||
ROC (Joel Greenblatt) % | -34.61 | |||||
ROCE % | -9.16 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 3431.72 | |||||
PS Ratio | 13.87 | |||||
PB Ratio | 4.22 | |||||
Price-to-Tangible-Book | 4.22 | |||||
EV-to-EBIT | -35.98 | |||||
EV-to-EBITDA | -44.57 | |||||
EV-to-Revenue | 11.61 | |||||
EV-to-FCF | -40.22 | |||||
Price-to-GF-Value | 1.09 | |||||
| Price-to-Net-Current-Asset-Value | 5.9 | |||||
| Price-to-Net-Cash | 7.53 | |||||
Earnings Yield (Greenblatt) % | -2.78 | |||||
FCF Yield % | -2.07 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alphamab Oncology Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 586.388 | ||
| EPS (TTM) (HK$) | -0.201 | ||
| Beta | 3.326 | ||
| 3-Year Sharpe Ratio | 0.38 | ||
| 3-Year Sortino Ratio | 0.76 | ||
| Volatility % | 74.01 | ||
| 14-Day RSI | 53.01 | ||
| 14-Day ATR (HK$) | 0.527218 | ||
| 20-Day SMA (HK$) | 8.33675 | ||
| 12-1 Month Momentum % | -23.93 | ||
| 52-Week Range (HK$) | 6.23 - 15.75 | ||
| Shares Outstanding (Mil) | 968.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alphamab Oncology Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alphamab Oncology Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Alphamab Oncology Frequently Asked Questions
What is Alphamab Oncology(HKSE:09966)'s stock price today?
The current price of HKSE:09966 is HK$8.43. The 52 week high of HKSE:09966 is HK$15.75 and 52 week low is HK$6.23.
When is next earnings date of Alphamab Oncology(HKSE:09966)?
The next earnings date of Alphamab Oncology(HKSE:09966) is .
Does Alphamab Oncology(HKSE:09966) pay dividends? If so, how much?
Alphamab Oncology(HKSE:09966) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Alphamab Oncology
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers